Rep. Marjorie Taylor Greene, a Peach State Republican and ardent Trump supporter, spoke with Fox News Digital about why she's ...

With so much in flux, it’s important to check with your employer or insurer about coverage policies before you roll up your ...

Should you get vaccinated? Will your insurer pay for it? And will you still be able to find a vaccine? KFF Health News tries ...

The company reported a net loss of $825 million for the quarter. Additionally, Moderna announced a $300 million reduction at the high end of their 2025 projected revenue range due to a timing shift of ...

Q2 2025 Earnings Call Transcript August 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.13, ...

Nevertheless, Moderna has lowered its revenue guidance for the year by $300 million. The company now expects to generate ...

Biotech firm aims to streamline operations and reinvest in high-growth areas such as oncology and rare diseases as it targets ...

Moderna beat Q2 earnings and revenue estimates, narrowed its annual forecast, won a key patent case, and plans to cut 10% of its global workforce.

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two years, it appears Moderna’s previous cost-cutting efforts haven’t g | ...

The mNEXSPIKE approval marks Moderna’s third FDA-approved product, giving them a heftier commercial portfolio than many investors give them credit for.

The new vaccine (mNexspike [COVID-19 Vaccine, mRNA]) represents a significant step forward in the development of next-generation coronavirus vaccines, the Associated Press reported.